Medinotec Inc.

Medinotec Inc. reported strong financial results for the first quarter ended May 31, 2026, with revenue increasing by 24.23% to $2.65 million and net income surging by 95.12% to $222,014. Diluted EPS doubled to $0.02. However, income from operations decreased by 34.81% to $180,872, primarily due to a significant increase in selling expenses. The company continues to rely heavily on a single customer, DISA Life Sciences, which accounted for 87% of total revenue.

Medinotec Inc. provided a comprehensive business update in its 10-K filing, detailing its operations as a medical device manufacturer and distributor. The company highlighted its proprietary products, including the Trachealator and Outflo Aortic Valve Dilation Balloon Catheter, both of which have received FDA 510(k) clearance. Medinotec is focused on expanding its product portfolio, developing internal capabilities, and evaluating strategic acquisitions, while managing a global distribution network across approximately 45 countries. The company reported US sales of $611,860 in fiscal 2026 and a decrease in compliance costs, but also noted an impairment allowance against a $750,000 receivable.